AKBA
Akebia Therapeutics, Inc.
$1.16
-1.69%
2026-05-08
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Key Fundamentals
Forward P/E
-7.28
EPS (TTM)
$-0.02
ROE
-79.0%
Revenue Growth (YoY)
-6.6%
Profit Margin
-8.8%
Debt/Equity
708.66
Price/Book
9.47
Beta
0.37
Market Cap
$312.5M
Avg Volume (10D)
3.4M
Recent Breakout Signals
No recent breakout signals detected for AKBA.
Recent Price Range (60 Days)
60D High
$1.60
60D Low
$1.13
Avg Volume
3.0M
Latest Close
$1.16
Get breakout alerts for AKBA
Sign up for Breakout Scanner to receive daily notifications when AKBA triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Akebia Therapeutics, Inc. (AKBA) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors AKBA daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. AKBA operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry. Data is provided for informational purposes only and does not constitute financial advice.